FTLP12

Across TCGA pan-cancer cohorts, FTLP12 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FTLP12’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where FTLP12 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FTLP12 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LIHC, KICH, and KIRC are the cancer types where FTLP12 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTLP12 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.570	<.001	7	view →
KICH	Male	All	−0.343	<.001	4	view →
KIRC	Female	II,III,IV	−0.161	.007	4	view →
KIRP	Male	III,IV	−0.121	.033	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

FTLP12–LIHC

Open the LIHC breakdown →